{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:09:44Z","timestamp":1793383784293,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T00:00:00Z","timestamp":1753401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100015389","name":"Suomen Onkologiayhdistys","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100015389","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017400","name":"Finnish Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017400","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008376","name":"Helsingin ja Uudenmaan Sairaanhoitopiiri","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008376","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007797","name":"Helsingin yliopisto","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007797","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-12596-1","type":"journal-article","created":{"date-parts":[[2025,7,25]],"date-time":"2025-07-25T10:34:05Z","timestamp":1753439645000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Finnish nationwide population-based study on the survival of patients with peripheral T-cell lymphoma"],"prefix":"10.1038","volume":"15","author":[{"given":"Taina","family":"Reunamo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilja","family":"Kalashnikov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kreetta","family":"Lahtela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjukka","family":"Pollari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leevi","family":"Viisanen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Mannisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sirkku","family":"Jyrkki\u00f6","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8265-511X","authenticated-orcid":false,"given":"Sirpa","family":"Lepp\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,25]]},"reference":[{"issue":"25","key":"12596_CR1","doi-asserted-by":"publisher","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","volume":"26","author":"JM Vose","year":"2008","unstructured":"Vose, J. M., Neumann, M. & Harris, M. E. International peripheral T-cell and natural killer\/T-cell lymphoma study: Pathology findings and clinical outcomes international T-cell lymphoma project. J Clin Oncol. 26(25), 4124\u20134130 (2008).","journal-title":"J Clin Oncol."},{"issue":"10","key":"12596_CR2","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood-2014-04-573089","volume":"124","author":"F Ellin","year":"2014","unstructured":"Ellin, F., Landstr\u00f6m, J., Jerkeman, M. & Relander, T. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: A study from the swedish lymphoma registry. Blood 124(10), 1570\u20131577 (2014).","journal-title":"Blood"},{"issue":"1","key":"12596_CR3","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdf033","volume":"13","author":"T R\u00fcdiger","year":"2002","unstructured":"R\u00fcdiger, T. et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the non-Hodgkin\u2019s lymphoma classification project. Ann. Oncol. 13(1), 140\u2013149 (2002).","journal-title":"Ann. Oncol."},{"issue":"7","key":"12596_CR4","doi-asserted-by":"publisher","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","volume":"36","author":"R Alaggio","year":"2022","unstructured":"Alaggio, R. et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: Lymphoid neoplasms. Leukemia 36(7), 1720\u20131748 (2022).","journal-title":"Leukemia"},{"issue":"20","key":"12596_CR5","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127(20), 2391\u20132405 (2016).","journal-title":"Blood"},{"issue":"9","key":"12596_CR6","doi-asserted-by":"publisher","first-page":"1009","DOI":"10.1182\/blood.2021015114","volume":"140","author":"M Brink","year":"2022","unstructured":"Brink, M. et al. Impact of etoposide and ASCT on survival among patients aged 65 years with stage II to IV PTCL: a population-based cohort study. Blood 140(9), 1009\u20132132 (2022).","journal-title":"Blood"},{"issue":"66","key":"12596_CR7","first-page":"75","volume":"48","author":"SS Wang","year":"2014","unstructured":"Wang, S. S. et al. Medical history, lifestyle, family history, and occupational risk factors for peripheral T-cell lymphomas: The interlymph non-hodgkin lymphoma subtypes project. J. Natl. Cancer Inst. Monogr. 48(66), 75 (2014).","journal-title":"J. Natl. Cancer Inst. Monogr."},{"issue":"10","key":"12596_CR8","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1093\/annonc\/mdh392","volume":"15","author":"KJ Savage","year":"2004","unstructured":"Savage, K. J., Chhanabhai, M., Gascoyne, R. D. & Connors, J. M. Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification. Ann. Oncol. 15(10), 1467\u20131475 (2004).","journal-title":"Ann. Oncol."},{"issue":"5","key":"12596_CR9","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1111\/bjh.14740","volume":"178","author":"H Cederleuf","year":"2017","unstructured":"Cederleuf, H. et al. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A nordic lymphoma group study. Br. J. Haematol. 178(5), 739\u2013746 (2017).","journal-title":"Br. J. Haematol."},{"issue":"6","key":"12596_CR10","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.annonc.2025.01.023","volume":"36","author":"F d'Amore","year":"2025","unstructured":"d\u2019Amore, F. et al. Peripheral T- and natural killer-cell lymphomas: ESMO-EHA clinical practice guideline for diagnosis, treatment, and follow-up. Ann. Oncol. 36(6), 626\u2013644 (2025).","journal-title":"Ann. Oncol."},{"key":"12596_CR11","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.2147\/OTT.S189825","volume":"12","author":"S Deng","year":"2019","unstructured":"Deng, S., Lin, S., Shen, J. & Zeng, Y. Comparison of CHOP vs CHOPE for treatment of peripheral T-cell lymphoma: A meta-analysis. Onco. Targets Ther. 12, 2335\u20132342 (2019).","journal-title":"Onco. Targets Ther."},{"issue":"24","key":"12596_CR12","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1182\/bloodadvances.2017010819","volume":"1","author":"YA Kim","year":"2017","unstructured":"Kim, Y. A. et al. Redefining the role of etoposide in first-line treatment of peripheral T-cell lymphoma. Blood Adv. 1(24), 2138\u20132146 (2017).","journal-title":"Blood Adv."},{"issue":"18","key":"12596_CR13","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","volume":"116","author":"N Schmitz","year":"2010","unstructured":"Schmitz, N. et al. Treatment and prognosis of mature T-cell and NK-cell lymphoma: An analysis of patients with T-cell lymphoma treated in studies of the german high-grade non-hodgkin lymphoma study group. Blood 116(18), 3418\u20133425 (2010).","journal-title":"Blood"},{"issue":"10168","key":"12596_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz, S. et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet 393(10168), 229\u2013240 (2019).","journal-title":"Lancet"},{"issue":"3","key":"12596_CR15","doi-asserted-by":"publisher","first-page":"285","DOI":"10.6004\/jnccn.2022.0015","volume":"20","author":"SM Horwitz","year":"2022","unstructured":"Horwitz, S. M. et al. Cell Lymphomas, Version 2.2022, NCCN clinical practice guidelines in oncology. J. Natl. Compr. Canc. Netw. 20(3), 285\u2013308 (2022).","journal-title":"J. Natl. Compr. Canc. Netw."},{"issue":"25","key":"12596_CR16","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1200\/JCO.2011.40.2719","volume":"30","author":"F d'Amore","year":"2012","unstructured":"d\u2019Amore, F. et al. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J. Clin. Oncol. 30(25), 3093\u20133099 (2012).","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"12596_CR17","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JCO.2008.17.4870","volume":"27","author":"P Reimer","year":"2009","unstructured":"Reimer, P. et al. Autologous stem-cell transplantation as first-line therapy in peripheral t-cell lymphomas: Results of a prospective multicenter study. J. Clin. Oncol. 27(1), 106\u2013113 (2009).","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"12596_CR18","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1002\/cncr.31861","volume":"125","author":"SI Park","year":"2019","unstructured":"Park, S. I. et al. The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study. Cancer 125(9), 1507\u20131517 (2019).","journal-title":"Cancer"},{"issue":"19","key":"12596_CR19","first-page":"2646","volume":"137","author":"N Schmitz","year":"2021","unstructured":"Schmitz, N. et al. A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood 137(19), 2646\u20132656 (2021).","journal-title":"Blood"},{"key":"12596_CR20","unstructured":"World Health Organization. Manual of the international statistical classification of diseases, injuries, and causes of death based on the recommendations of the seventh revision Conference, 1955, and adopted by the ninth World Health Assembly under the WHO Nomenclature Regulations. (1957). https:\/\/ apps.who.int\/iris\/handle\/10665\/42900. 1955"},{"key":"12596_CR21","volume-title":"Manual of tumor nomenclature and coding","author":"American Cancer Society","year":"1951","unstructured":"American Cancer Society. Manual of tumor nomenclature and coding (American Cancer Society, 1951)."},{"key":"12596_CR22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ejca.2017.02.017","volume":"77","author":"MK Leinonen","year":"2017","unstructured":"Leinonen, M. K., Miettinen, J., Heikkinen, S., Pitk\u00e4niemi, J. & Malila, N. Quality measures of the population-based finnish cancer registry indicate sound data quality for solid malignant tumours. Eur. J. Cancer Oxf. Engl. 77, 31\u201339 (2017).","journal-title":"Eur. J. Cancer Oxf. Engl."},{"key":"12596_CR23","unstructured":"Ederer F., Heise H . Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. Bethesda: National Cancer Institute; 1959."},{"key":"12596_CR24","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/(SICI)1097-0142(19961101)78:9<2004::AID-CNCR23>3.0.CO;2-#","volume":"78","author":"H Brenner","year":"1996","unstructured":"Brenner, H. & Gefeller, O. An alternative approach to monitoring cancer patient survival. Cancer 78, 2004\u20132010 (1996).","journal-title":"Cancer"},{"issue":"12","key":"12596_CR25","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1080\/10428194.2017.1300888","volume":"58","author":"H Cederleuf","year":"2017","unstructured":"Cederleuf, H. et al. Outcome of peripheral T-cell lymphoma in first complete remission: A Danish-Swedish population-based study. Leuk Lymphoma. 58(12), 2815\u20132823 (2017).","journal-title":"Leuk Lymphoma."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12596-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12596-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T00:46:58Z","timestamp":1757292418000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-12596-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,25]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["12596"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-12596-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,25]]},"assertion":[{"value":"26 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"27077"}}